Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 9/20 | 0.53 |
| ▸ | PRKD1 | Q15139 | 2/20 | 0.53 |
| ▸ | PAK4 | O96013 | 2/20 | 0.39 |
| ▸ | ROCK1 | Q13464 | 6/20 | 0.39 |
| ▸ | CDC7 | O00311 | 7/20 | 0.37 |
| ▸ | CDK2 | P24941 | 6/20 | 0.37 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.37 |
| ▸ | PAK2 | Q13177 | 1/20 | 0.37 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.37 |
| ▸ | PAK6 | Q9NQU5 | 1/20 | 0.37 |
| ▸ | PAK5 | Q9P286 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11970502 | 0.87 | MAP3K14 (0.46) | MAP3K14PRKD1PAK4ROCK1CDC7 | |
| SCHEMBL11970929 | 0.86 | MAP3K14 (0.45) | MAP3K14PRKD1PAK4ROCK1CDC7 | |
| SCHEMBL11970865 | 0.86 | MAP3K14 (0.53) | MAP3K14PRKD1PAK4ROCK1CDC7 | |
| SCHEMBL11970324 | 0.83 | MAP3K14 (0.60) | MAP3K14PRKD1PAK4CDC7CDK2 | |
| SCHEMBL12001441 | 0.82 | MAP3K14 (0.59) | MAP3K14PRKD1PAK4ROCK1CDC7 | |
| SCHEMBL11970535 | 0.80 | MAP3K14 (0.64) | MAP3K14PRKD1PAK4CDC7CDK2 | |
| SCHEMBL11970735 | 0.78 | MAP3K14 (0.74) | MAP3K14PRKD1PAK4PAK1PAK2 | |
| SCHEMBL12001476 | 0.78 | MAP3K14 (0.55) | MAP3K14PRKD1PAK4ROCK1CDC7 | |
| SCHEMBL11971104 | 0.76 | MAP3K14 (0.51) | MAP3K14PAK4ROCK1CDC7CDK2 | |
| SCHEMBL12001641 | 0.75 | MAP3K14 (0.48) | MAP3K14PRKD1PAK4ROCK1CDC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150038460-A1 | 6,5-Heterocyclic Propargylic Alcohol Compounds and Uses Therefor | GENENTECH, INC. (US) | 2015-02-05 | — | — | US | disclosed |
| US-20150038460-A1 | 6,5-Heterocyclic Propargylic Alcohol Compounds and Uses Therefor | GENENTECH, INC. (US) | 2015-02-05 | — | — | US | disclosed |
| US-20150038460-A1 | 6,5-Heterocyclic Propargylic Alcohol Compounds and Uses Therefor | GENENTECH, INC. (US) | 2015-02-05 | — | — | US | disclosed |
| US-8901313-B2 | 6,5-heterocyclic propargylic alcohol compounds and uses therefor | GENENTECH, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-8901313-B2 | 6,5-heterocyclic propargylic alcohol compounds and uses therefor | GENENTECH, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| US-8901313-B2 | 6,5-heterocyclic propargylic alcohol compounds and uses therefor | GENENTECH, INC. (US) | 2014-12-02 | — | — | US | disclosed |
| WO-2014170421-A1 | SERINE/THREONINE KINASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-10-23 | — | — | WO | disclosed |
| EP-2686314-A1 | 6,5-HETEROCYCLIC PROPARGYLIC ALCOHOL COMPOUNDS AND USES THEREFOR | F.HOFFMANN-LA ROCHE AG (CH) | 2014-01-22 | — | — | EP | disclosed |
| WO-2012123522-A1 | 6,5-HETEROCYCLIC PROPARGYLIC ALCOHOL COMPOUNDS AND USES THEREFOR | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-20 | — | — | WO | disclosed |
| WO-2012123522-A1 | 6,5-HETEROCYCLIC PROPARGYLIC ALCOHOL COMPOUNDS AND USES THEREFOR | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-20 | — | — | WO | disclosed |
| US-20120214762-A1 | 6,5-HETEROCYCLIC PROPARGYLIC ALCOHOL COMPOUNDS AND USES THEREFOR | GENENTECH, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-20120214762-A1 | 6,5-HETEROCYCLIC PROPARGYLIC ALCOHOL COMPOUNDS AND USES THEREFOR | GENENTECH, INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-20120214762-A1 | 6,5-HETEROCYCLIC PROPARGYLIC ALCOHOL COMPOUNDS AND USES THEREFOR | GENENTECH, INC. (US) | 2012-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120214762-A1 | 6,5-HETEROCYCLIC PROPARGYLIC ALCOHOL COMPOUNDS AND USES THEREFOR | NFKB1, NFRKB, NFKBIA | MAP3K14 519/4885PRKD1 1505/4885PAK4 1856/4885 |
| US-20150038460-A1 | 6,5-Heterocyclic Propargylic Alcohol Compounds and Uses Therefor | NFKB1, NFRKB, NFKBIA | MAP3K14 519/4885PRKD1 1505/4885PAK4 1856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.